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Brain aging is characterized by progressive loss of neurophysiological functions that is
often accompanied by age-associated neurodegeneration. Calorie restriction has been
linked to extension of lifespan and reduction of the risk of neurodegenerative diseases in
experimental model systems. Several signaling pathways have been indicated to underlie
the beneﬁcial effects of calorie restriction, among which the sirtuin family has been
suggested to play a central role. In mammals, it has been established that sirtuins regulate
physiological responses to metabolism and stress, two key factors that affect the process
of aging. Sirtuins represent a promising new class of conserved deacetylases that play
an important role in regulating metabolism and aging. This review focuses on current
understanding of the relation between metabolic pathways involving sirtuins and the
brain aging process, with focus on SIRT1 and SIRT3. Identiﬁcation of therapeutic agents
capable of modulating the expression and/or activity of sirtuins is expected to provide
promising strategies for ameliorating neurodegeneration. Future investigations regarding
the concerted interplay of the different sirtuins will help us understand more about the
aging process, and potentially lead to the development of therapeutic approaches for the
treatment of age-related neurodegenerative diseases and promotion of successful aging.
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INTRODUCTION
The brain, similar to other organs, undergoes a gradual decline in
energy metabolism during aging (Drew and Leeuwenburgh, 2004;
Navarro and Boveris, 2007; Boveris and Navarro, 2008; Swerd-
low, 2011). Since neurons require large amounts of energy for
the ﬁring of action potential, neurotransmission, and other pro-
cesses, the age-related decline in metabolism contributes to the
cognitive declines associated with aging (Biessels and Kappelle,
2005; Boveris and Navarro, 2008). Aging is also a risk factor for
age-associated diseases such as neurodegenerative disorders. These
diseases may occur when neurons fail to respond adaptively to an
age-related decline in basal metabolic rates and in energy-driven
tasks, such as neuromuscular coordination, cognitive perfor-
mance, and environmental awareness (Swerdlow, 2007). In the
past decade, the function of mammalian sirtuins, evolutionarily
conserved nicotinamide adenine dinucleotide (NAD)-dependent
protein deacetylases/ADP-ribosyltransferases, has been investi-
gated in greater detail, and we now have a much better molecular
understanding of the multiple roles that this unique family of
enzymes plays in aging and seemingly every biological process.
There is little doubt that sirtuins have emerged as critical mod-
ulators of metabolic adaptive responses, and their activities have
been linked to multiple diseases, from metabolic abnormalities to
neurodegeneration.
Sirtuins were originally identiﬁed as one of the genes that
regulate the mating types of budding yeast, Saccharomyces cere-
visiae, and named silent information regulator 2 (Sir2) in lower
organisms (Klar and Fogel, 1979). Following the ﬁrst publi-
cation describing a role for yeast Sir2 in promoting longevity
(Kaeberlein et al., 1999), many investigations focused on elucidat-
ing whether sirtuins might play similar roles in other organisms.
Sirtuins have been shown to regulate lifespan in lower organ-
isms, including yeast, nematodes, and fruit ﬂies (Haigis and
Guarente, 2006), although their role in worm and ﬂy lifespan
has recently been debated (Burnett et al., 2011; Viswanathan and
Guarente, 2011). Most of these studies have described a key role
for SIRT1 in regulating the metabolic response to calorie restric-
tion (CR; Canto and Auwerx, 2009), a dietary intervention that
robustly extends life span across numerous species. However,
whole body overexpression of SIRT1 in mice does not affect life
span (Herranz et al., 2010). Nevertheless, SIRT1 does appear to
promote healthy aging by protecting against several age-related
pathologies, such as facilitating insulin sensitivity, elevating glu-
cose production, reducing oxidative stress, potentiating activity of
brain-derived neurotrophic factor (BDNF) transcriptional factor
cAMP response element-binding protein (CREB; Guarente and
Franklin, 2011).
Mammals have seven sirtuins (SIRT1–7)which are found indif-
ferent subcellular locations, including the nucleus (SIRT1, SIRT6,
and SIRT7), cytosol (SIRT2), and mitochondria (SIRT3, SIRT4,
and SIRT5).Most of the studies have described a key role for SIRT1
in regulating the metabolic response to CR (Canto and Auwerx,
2009), a dietary regimen involving reduced 30–40% calorie intake
compared to normal calorie intake, that resulted in extended lifes-
pan and reduceddevelopment ofmorbiditywith aging (Jiang et al.,
2000; Masoro, 2000; Sinclair, 2002; Koubova and Guarente, 2003).
Calorie restriction is the only intervention that has consistently
been shown to delay the onset, slow the progression of age-related
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disease, and extend lifespan in short-lived species, as well as in
long-lived non-human primates, suggesting that similar mecha-
nisms would be operative in humans. Whole body overexpression
of Sirt1 in mice does not affect lifespan (Herranz et al., 2010).
Nevertheless, SIRT1 promotes healthy aging by preventing age-
associated pathologies (Guarente and Franklin, 2011). Another
strong link betweenmammalian sirtuins and the anti-aging effects
of CR was provided by SIRT3, which mediates the prevention of
age-related hearing loss (Someya et al., 2010). SIRT3 is required for
the CR-mediated reduction of oxidative damage in multiple tis-
sues via regulation of the glutathione antioxidant system (Someya
et al., 2010).
In this review, we focus on the effects of SIRT1 and SIRT3
on metabolic regulation and their anti-aging activity in brain,
and further discuss potential pharmacological approaches to rem-
edy and prevent age-associated neurological disorders by targeting
sirtuins.
SIRT1, METABOLISM AND BRAIN AGING
DISTRIBUTION OF SIRT1 IN THE BRAIN
During mouse embryogenesis, SIRT1 is highly expressed in the
brain, spinal cord, and dorsal root ganglion, with the peak expres-
sion at E4.5 (Salminen and Kaarniranta, 2012). SIRT1 is also
expressed in the adult brain, with high levels in the cortex, hip-
pocampus, cerebellum, and hypothalamus, and low levels in white
matter (Singh, 2004). Among the various cell types of brain, SIRT1
is predominantly, if not exclusively, expressed in neurons (Singh,
2004; Adler et al., 2007; Salminen and Kaarniranta, 2012). The
only exception is that SIRT1 is found in microglia when co-
cultured with neurons (Schmitz et al., 2004). At the subcellular
level, SIRT1 is viewed as a nuclear protein (Chen and Greene,
2003). Yet it is reported that SIRT1 has both nuclear import
and export sequences, and that SIRT1 is present in the cytoso-
lic fraction of mouse brain, although its cytosolic function is just
beginning to be elucidated (Chen et al., 2005b; Lee et al., 2008;
Hardie, 2011).
SIRT1 MEDIATES METABOLIC BENEFITS UNDER CR
SIRT1 contains 747 amino acids in humans, with a predicted
molecular weight of 81 kDa and a measured one of 120 kDa.
In addition to histones, SIRT1 also deacetylates a number of non-
histone substrates, including p53 (Luo et al., 2001)and peroxisome
proliferator-activated receptor γ (PPARγ) coactivator-1α (PGC-
1α; Nemoto et al., 2005), and FOXO (Xiong et al., 2011), nuclear
factor κ-light-chain-enhancer of activated B cells (NF-κB; Salmi-
nen et al., 2008b). SIRT1 is drawing even more attention since it is
considered to be one of the determining factors in lifespan exten-
sion induced by CR, a phenomenon observed in phylogenetically
diverse organisms including yeast, worm, fruit ﬂy, and mouse
(Kaeberlein et al., 1999; Tissenbaum and Guarente, 2001; Howitz
et al., 2003; Rogina and Helfand, 2004). Its beneﬁcial roles are
further supported by the ﬁndings that putative SIRT1-activating
compounds, such as resveratrol, also promote longevity in sev-
eral species, including yeast (Howitz et al., 2003), worm (Wood
et al., 2004), andmouse (Baur et al., 2006),making it an anti-aging
target.
The effects of SIRT1 on longevity rely on its enzymatic activ-
ity of deacetylation of histone and non-histone substrates. While
the deacetylation of histones leads to their interaction with DNA
and consequent gene silencing (Braunstein et al., 1993; Sauve et al.,
2006; Dali-Youcef et al., 2007), the deacetylation of non-histone
proteins has a wide range of biological effects, includingmetabolic
adjustment, survival promotion, and autophagy (Campisi, 2005;
Dali-Youcef et al., 2007; Brooks and Gu, 2009; Madeo et al., 2010).
For example, SIRT1 inhibits p53 (Luo et al., 2001), reducing its
pro-apoptotic effect. It also inhibits NF-κB (Yeung et al., 2004),
reducing its pro-inﬂammatory effects. In contrast, SIRT1 acti-
vates a transcriptional coactivator, PGC-1α (Nemoto et al., 2005),
leading to increased glucose levels, insulin sensitivity, and mito-
chondrial biogenesis. Together, these and other effects, contribute
to the longevity evoked by CR (Figure 1).
These metabolic changes and the cytoprotective involvement
of CR are generally considered to occur in non-neural organs,
such as the liver, pancreas, muscle, and fat tissues (Brooks and Gu,
2009; Imai and Guarente, 2010). However, recent studies suggest
that the hypothalamus may also contribute to the longevity effects
of SIRT1 and CR via coordination of neurobehavioral and neu-
roendocrine changes, including body temperature, appetite, and
overall physical activity (Dietrich et al., 2010; Satoh et al., 2010).
SIRT1 is abundantly expressed in several regions in the hypothala-
mus of mice, especially in the arcuate, paraventricular, ventro-
and dorsomedial nuclei; and CR increases SIRT1 levels in the
hypothalamus, which increases body temperature, food intake,
and physical activity (Ramadori et al., 2008; Dietrich et al., 2010;
Satoh et al., 2010). SIRT1 appears to be required for the afore-
mentioned behavioral changes, which are prevented if SIRT1 is
knocked out or inhibited (Chen et al., 2005a; Satoh et al., 2010). In
addition to the hypothalamus, SIRT1 is also expressed in other
regions of the brain, including the cortex, striatum, and hip-
pocampus (Ramadori et al., 2008). Shortly after this ﬁnding, a
neuroprotective role of SIRT1, has been reported (Tang, 2009;
Morris et al., 2011).
SIRT1 AND FACTORS INVOLVED IN CR AND AGING
SIRT1 has been found to delay aging and promote longevity by
regulating the activity of key cellular proteins like p53, FOXO and
Ku70 that are involved in either apoptotic processes or cellular
repairmechanisms. SIRT1may thus promote health and longevity
partly by either decelerating cell death and/or by boosting repair
mechanisms in the cells (Wang et al., 2010).
It has become increasingly evident that the salutary effects of
the CR, are in part due to the promotion of sirtuins (Wang et al.,
2010). The expression levels of SIRT1 increase upon CR in several
rodent and human tissues, including white adipose, liver, skeletal
muscle, brain, and kidney. Levels of NAD have been shown to
rise in liver cells under CR-like conditions, which in turn induces
expression of SIRT1 (Rodgers et al., 2005). SIRT1 ends up con-
suming NAD+ as a result of its deacetylase activity, generating
nicotinamide, an inhibitor of its own activity. NAD+ is known
to protect neurons (Liu et al., 2009) and thus by increasing the
levels of NAD+, CR may preserveSIRT1 activity. SIRT1 also acti-
vates PGC1α (Rodgers et al., 2005) which results in mitochondrial
biogenesis (Liu et al., 2009). A decline in mitochondrial activity
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FIGURE 1 | Schematic diagram of anti-aging mechanism activated by
SIRT1 and calorie restriction. Calorie restriction upregulates the activity and
levels of SIRT1, SIRT1 deacetylates its substrates, including histone and
non-histone molecules, and improve genome stability, prevent apoptosis and
inﬂammation, and increases mitochondrial biogenesis, insulin sensitivity and
glucose tolerance. All these effects result in longevity.
is thought to be causative in many age-related diseases (Petersen
et al., 2003; Singh, 2004). CR evokes improvements in mitochon-
drial activity similar to those of SIRT1. Therefore, it is possible that
small-molecule modulators of SIRT1 may act on the same path-
ways as those modiﬁed by CR, and thus have potential to mitigate
age-related diseases (Lavu et al., 2008).
SIRT1 interacts with and modulates other key factors involved
in mammalian aging, such as NF-κB that controls a low-grade
systemic inﬂammation alongwith human aging process-inﬂamm-
aging (Salminen et al., 2008a), mammalian target of rapamycin
(mTOR; Finley and Haigis, 2009), AMP-activated protein kinase
(AMPK; Salminen and Kaarniranta, 2012), therefore controls the
gin process. The aging process involves changes in immune reg-
ulation; NF-κB signaling is the master regulator of the immune
system. Inhibition of NF-κB signaling in aged mice reverted the
tissue characteristics and global gene expression to those of young
mice (Adler et al., 2007). The function of the NFκB complex can
be regulated by the acetylation of the p65 component (Schmitz
et al., 2004). SIRT1 can interact with RelA/p65 protein in the NF-
κB complex and speciﬁcally deacetylates lysine 310, which has
been demonstrated to potentiate the transactivation capacity of
the NFκB complex (Chen and Greene, 2003). Several studies have
indicated that SIRT1 is a potent inhibitor of NF-κB transcription
(Yeung et al., 2004; Chen et al., 2005b). The signaling link between
SIRT1 and NF-κB is especially interesting with respect to aging, as
a consequence of the release of the SIRT1brake, the transactivation
efﬁciency of NF-κB factor is potentiated, which evokes immune
activation and inﬂamm-aging.
Aging process is also regulated by autophagy. It has been
identiﬁed the signaling pathways that regulate autophagic degra-
dation and SIRT1 is a potent regulator of autophagic degradation
(Lee et al., 2008), SIRT1 can interact with and deacetylates sev-
eral components in the complexes of forming autophagosomes,
such as Atg5, Atg7, and Atg8 proteins (Lee et al., 2008). There is
a clear overlap between the signaling networks regulating both
aging and autophagocytosis, which emphasizes the important role
of autophagy in the regulating of aging and age-related degen-
erative diseases. It is evident that increase in autophagy can
extend lifespan. mTOR activity is suppressed by CR, reduction
in mTOR signaling is a logic candidate mechanism for the anti-
agingbeneﬁts of CR.Throughdeacetylationof a variety of proteins
involved in autophagy process, SIRT1 can regulate physiological
process during aging and moderated by CR (Haigis and Guarente,
2006).
Efﬁcient control of energy metabolic homeostasis is a hallmark
of improved healthspan and extended lifespan. The AMPK and
SIRT1 signaling pathways are highly conserved energy sensor of
increased levels of AMP and NAD+, respectively, AMPK signal-
ing is involved in the regulation of energy metabolic homeostasis
(Hardie, 2011). Canto and Auwerx (2009) demonstrated that the
activation of AMPK stimulated the functional activity of SIRT1 by
increasing the intracellular concentration of NAD+. Interestingly,
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SIRT1 was able to deacetylate LKB1 kinase which subsequently
increased its activity (Lan et al., 2008). Since LKB1 is an upstream
activator of AMPK, this signaling pathway stimulates the activa-
tion of AMPK. This positive feedback loop between SIRT1 and
AMPK can also potentiate the function of the other AMPK-
activated signaling pathways. The close relationship between
AMPK and SIRT1 is evidence that energy balance effectively
controls cellular responses via an integrated signaling network.
AMPK can inhibit the activity of mTOR complex via two differ-
ent mechanisms, either by directly phosphorylating the Raptor,
a regulatory component of mTORC1, or by the phosphoryla-
tion of tuberous sclerosis protein 2 (TSC2), which subsequently
suppresses the activity of mTOR (Jung et al., 2010; Mihaylova
and Shaw, 2011). Taken together, SIRT1 interacts with other key
anti-aging signaling pathways thereby contributing to longevity
control.
It has been established that aging is a known risk factor for
many neurodegenerative diseases including Alzheimer’s disease
(AD), Parkinson’s disease (PD), Wallerian neurodegeneration,
Huntington’s disease (HD), and amyotrophic lateral sclerosis
(ALS). The pathomechanisms involved in these disorders involve
common biochemical pathways and processes, including protein
misfolding, oligomerization, and aggregation, proteolysis, post-
translationalmodiﬁcations,mitochondrial dysfunction, abnormal
metabolic processes, and proinﬂammatory and proapoptotic
responses that we discuss in the next section.
SIRT1 AND AGE-ASSOCIATED NEUROLOGICAL DISEASES
Wallerian degeneration
Wallerian degeneration refers to axonal death and degradation
after focal injury, followed by breakdown of myelin sheath. The
neuroprotective effect of SIRT1 against Wallerian degeneration
was ﬁrst discovered in wlds transgenic mice (Perry et al., 1990).
These mice exhibited a signiﬁcant delay in axonal degeneration
after physical or chemical injury. The mechanistic basis for the
delayed axonal damage was apparently associated with the mutant
wlds chimeric protein. It has been shown that Nicotinamide
mononucleotide adenylyltransferase 1 (NMNAT-1) activity plays
an important role in the prevention of axonal damage, exerting its
protective effects through SIRT1 activation, as the neuroprotec-
tion is blocked by the SIRT1 inhibitor sirtinol or siRNA-mediated
SIRT1 silencing (Araki et al., 2004; Sasaki et al., 2009; Babetto
et al., 2010). The role of SIRT1 remains controversial, however,
as both SIRT1-dependent (Araki et al., 2004) and -independent
mechanisms are reported (Wang et al., 2005b).
Alzheimer’s disease
Alzheimer’s disease is a terminal neurodegenerative disease, caus-
ing neuronal death and brain atrophy. The pathological hallmarks
of AD are the intracellular tangles and extracellular plaques in
brain. The tangles, also known as neuroﬁbrillary tangles, are
formed by accumulation of insoluble tau proteins, and the plaques
are deposits of β-amyloid (Aβ) peptides, typically consisting of
40–42 amino acid residues.
The protective effect of SIRT1 against ADwas initially observed
in CR studies, where CR reduced Aβ and plaque generation
in the brains of transgenic AD mice (Patel et al., 2005; Wang
et al., 2005a). Similarly, the reduction of Aβ was also noticed in
the cortex of fasted squirrel monkeys and is inversely correlated
with SIRT1 levels (Qin et al., 2006a). These studies imply that
SIRT1 is involved in neuroprotection against AD. Indeed, recent
studies demonstrate that SIRT1 activation reduces the neuronal
death and brain atrophy that are characteristic of AD (Chen et al.,
2005b; Qin et al., 2006b; Kim et al., 2007; Donmez et al., 2010;
Min et al., 2010). SIRT1 deﬁciency is associated with increased
levels of phosphorylated-tau in neurons (Min et al., 2010) and
the amount of neuroﬁbrillary tangles in AD brains (Julien et al.,
2009).
Moreover, recent studies show that either administration of
resveratrol or overexpression of SIRT1 reduces Aβ levels both
in vitro and in vivo (Chen et al., 2005b; Qin et al., 2006b; Don-
mez et al., 2010). SIRT1 overexpression stimulates the production
of α-secretase in neurons and mice by two pathways: acti-
vating the retinoic acid receptor (RAR; Donmez et al., 2010)
and inhibiting the rho-associated, coiled-coil-containing protein
kinase 1 (ROCK1; Qin et al., 2006b). Increased levels of α-secretase
enhance normal process of Amyloid precursor protein (APP),
leading to decreased generation of toxic Aβ. In addition, SIRT1
also reduces the NF-kappaB pathway in microglia and decreases
Aβ level (Chen et al., 2005b). Taken together, these results establish
that SIRT1 protects againstADbymultiplemechanisms, including
degradation of tau and reducing levels of Aβ.
Parkinson’s disease
Parkinson’s disease is a commonneurodegenerative disease caused
by the death of dopaminergic neurons of the substantia nigra in
themidbrain. Themajor symptoms of PD are rigidity, tremor, and
bradykinesia. Our early study found that CR or use of 2-deoxy-
D-glucose, a glucose analog, reduces the loss of dopaminergic
neurons in mice and improves motor function, implying that
SIRT1 may be involved in the protection (Duan and Mattson,
1999). The levels of SIRT1 in dopaminergic neurons are sharply
decreased by treatment with neurotoxins, such as rotenone,
6-hydroxydopamine, α-synuclein, or 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP; Alvira et al., 2007; Pallas et al., 2008;
Albani et al., 2009), which are agents widely used to model PD.
Additionally, SIRT1 overexpression (Wareski et al., 2009) or acti-
vation by resveratrol (Okawara et al., 2007; Chao et al., 2008;
Albani et al., 2009) slows neuronal death as well as neurodegen-
eration in PD models both in vivo and in vitro (Donmez et al.,
2012), indicating a neuroprotective role of SIRT1 against PD.
Not all studies showed a protective role of SIRT1, however. For
example, no protection was observed in an MPTP-induced PD
model in SIRT1 transgenic mice (Kakefuda et al., 2009). Nev-
ertheless, despite the controversy, most research demonstrates a
protective role of SIRT1 against PD, although the mechanisms are
unclear.
Huntington’s disease
Huntington’s disease is an autosomal dominant hereditary dis-
ease with onset in middle-age. It is caused by a trinucleotide
repeat mutation in the huntingtin gene that results in an increased
number of glutamine residues in the N-terminus of the hunt-
ingtin protein which causes abnormal protein aggregation and
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ultimately neuronal death. Our previous study showed that CR
could ameliorate the motor phenotype and extend survival of
HD mice (Duan et al., 2003), indicating that pathways related to
energy metabolism can modify disease progression in the disease.
CR increases mitochondrial biogenesis by inducing endothelial
nitric oxide synthase (eNOS), and NO can activate the SIRT1
gene (Nisoli et al., 2005; Haigis and Guarente, 2006), which is
the mammalian ortholog of yeast Sir2, and a highly conserved
NAD+-dependent protein deacetylase. Moreover, SIRT1 has been
suggested to mediate some beneﬁcial effects of CR (Canto and
Auwerx, 2009; Wakeling et al., 2009; Shimokawa and Trindade,
2010; Chalkiadaki and Guarente, 2012).
The ﬁrst report demonstrating the connection between SIRT1
and HD came from studies by Parker et al. (2005), who found that
overexpression of Sir2.1 or treatmentwith resveratrol rescuedneu-
ronal dysfunction phenotypes induced by mutant polyglutamine
in Caenorhabditis elegans. In contrast to the neuroprotective
effect of Sir2.1 in C. elegans, Pallos et al. (2008) reported that
50% reduction of Sir2 extended survival and preserved neurons
containing photoreceptor in ﬂies expressing mutant Htt. Inter-
estingly, in the ﬂy model system, overexpression of Sir2 does
not reduce the lethality or the level of neuronal degeneration
caused by mutant Htt. Studies in both C. elegans and Drosophila
suggest that complete loss of Sir2 is deleterious in the worm
(Parker et al., 2005) and is deleterious compared with heterozy-
gous loss in mutant Htt-challenged ﬂies (Pallos et al., 2008).
Although heterozygous loss of Sir2 is protective in ﬂies, het-
erozygous loss of Sir2 in worms was not examined. Nevertheless,
reduction of Sir2 neither alters the life-span of ﬂies not express-
ing Htt nor siblings expressing Htt. Several aspects of the role
of sirtuins in lifespan in C. elegans and Drosophila are contro-
versial, and studies have indicated that Sir2 overexpression did
not increase lifespan and that dietary restriction increased lifespan
in ﬂies independently of dSir2 (Burnett et al., 2011). Nonethe-
less, overexpression of Sir2 increases the longevity of normal
ﬂies and the longevity of diseased ﬂies is slightly increased by
elevated Sir2 (Pallos et al., 2008). The different results might be
due to the amount of Sir2, its activation status, and different
downstream targets involved. These controversial results war-
rant further investigation of the role of SIRT1 in mammalian
systems.
Indeed, two independent studies by our group (Jiang et al.,
2011) and Krainc’s group (Jeong et al., 2011) demonstrated that
modulating the levels of SIRT1 has therapeutic beneﬁt in three
different HD mouse models, and putative downstream targets
of SIRT1 involved in improved disease outcomes are also iden-
tiﬁed. These two studies provide compelling support to the
view that SIRT1 provides beneﬁcial effects in HD mouse mod-
els, but also raise important questions. It is possible that the
contradictory results on the effects of SIRT1 in models of HD
might be explained by different effector pathways or mechanisms
and by context-dependent effects or different levels of SIRT1
activation. SIRT1 has numerous targets, and different models
of HD display different phenotypes by activating various tar-
gets and mechanisms. Therefore, it is not surprising to observe
contradictory data, especially in different species and different
models.
AMYOTROPHIC LATERAL SCLEROSIS
Amyotrophic lateral sclerosis is a chronic, fatal neurodegenerative
disease, characterized pathologically by the death of motor neu-
rons in the spinal cord and cortex, possibly induced by a deﬁciency
in the enzyme superoxide dismutase 1 (SOD1; Rosen, 1993). In the
animal model of ALS where a mutant form of SOD1 is expressed,
SIRT1 levels are upregulated in motor neurons (Kim et al., 2007).
SIRT1 overexpression protects neurons against toxicity induced by
themutant SOD1 in both cultured neurons andmouse brain (Kim
et al., 2007). This protection corresponds to the increased deacety-
lation of p53. Resveratrol also enhances the protective effect of
SIRT1 in a mouse model of ALS (Kim et al., 2007; Markert et al.,
2010), but multiple doses are appear to be necessary to improve
neurological function and increase the longevity of mice (Markert
et al., 2010).
Multiple sclerosis
Multiple sclerosis is a myelin sheath disease with lesions typically
located in the brain, spinal cord or cranial nerves, and, most com-
monly, in the optic nerve. The causes of multiple sclerosis are
not fully identiﬁed but likely arise from an autoimmune etiology;
therefore, it is traditionally treated as an inﬂammatory disease.
Recently, however, multiple sclerosis has also been considered
to be a neurodegenerative disease because of the co-existence of
permanent axonal damage, neuronal loss, and neurological dis-
ability in patients with the disease (Lassmann, 2010; Shindler
et al., 2010). In a mouse model of multiple sclerosis, experimen-
tal autoimmune encephalomyelitis (EAE), SIRT1 activation by
SRT501 or SRT1720 maintains axonal density, prevents neuronal
loss, and improves neuronal dysfunction (Shindler et al., 2007,
2010). SIRT1 inhibition with Sirtinol attenuates the neuroprotec-
tive effects of SRT501 (Shindler et al., 2010), suggesting aprotective
role of SIRT1 in multiple sclerosis. However, further investiga-
tions are necessary to fully delineate the role of SIRT1 in multiple
sclerosis.
Cerebral ischemia
Ischemic stroke is a common neurological disease caused by the
sudden reduction or cessation of blood ﬂow to the brain, leading
to infarction. The clinical management of stroke is difﬁcult and
current drugs must be administered within a limited time window
after the onset of the stroke to provide clinical beneﬁt. Promising
candidates for neuroprotective strategies include preconditioning,
mild hypothermia, and the use of chemical and biological com-
pounds targeting critical molecular mediators of neuronal death
and survival.
The neuroprotective effect of SIRT1 was ﬁrst reported in
ischemic preconditioning and the SIRT1 activating compound
resveratrol reduced neuronal injury of the hippocampus in global
cerebral ischemia in rats. Increased SIRT1 activity was also shown
to be a common mechanism for the protective effects of pre-
conditioning and resveratrol (Raval et al., 2006; Morris et al.,
2011). Sirtinol, an inhibitor of SIRT1 activity, abolished the
neuroprotection of preconditioning and resveratrol (Raval et al.,
2006), indicating that SIRT1 plays a key role in mediating neu-
roprotection. This neuroprotective role is further supported by
two recent studies (Chong and Maiese, 2008; Della-Morte et al.,
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2009) showing that SIRT1 activation reduces ischemic neuronal
injuries.
Another study showed that, in primary neuronal culture, pre-
treatment with NAD+ pretreatment markedly reduces neuronal
death induced by oxygen-glucose deprivation, an in vitromodel of
ischemia (Wang et al., 2008). SIRT1 is necessary for NAD+ neuro-
protection, as NAD+ treatment upregulates SIRT1 expression and
activity, andSIRT1knockdownattenuates the protectionmediated
by NAD+ (Wang et al., 2008). NAMPT overexpression reduces
ischemic infarct, whereas NAMPT inhibition aggravates ischemic
injuries. The protective effect of NAMPT is SIRT1-dependent, as
SIRT1 knockout blocks the protection (Wang et al., 2011).
Despite the aforementioned evidence, controversy exists over
the protective effect of SIRT1 against ischemia. In a study with
SIRT1 transgenic mice, where human SIRT1 was overexpressed
under the control of rat neuron-speciﬁc enolase promoter, no
neuroprotection was observed against stroke as SIRT1 and wild-
type mice demonstrated almost indistinguishable infarct volumes
and neurological deﬁciency scores (Kakefuda et al., 2009). The dis-
crepancy between this study and the others was probably due to
the sustained high level of SIRT1, because it may consume too
much or even deplete NAD+, which could exaggerate neuronal
injury (Wang et al., 2008; Kakefuda et al., 2009; Liu et al., 2009).
Therefore, it is possible that NAD+ deﬁciency compromised the
neuroprotective effect of SIRT1. In another study, nicotinamide,
a compound that inhibits SIRT1 action, showed neuroprotection
against ischemic injury, implying that SIRT1 might have a detri-
mental effect against stroke (Chong et al., 2005). However, this
report might overlook other functions of nicotinamide, including
that of precursor for NAD+ synthesis. In fact, the same group
later reported that SIRT1 overexpression prevents neurons from
apoptosis after oxidative stress (Chong and Maiese, 2008).
SIRT1 IN CLINICAL PRACTICE
SIRT1-activating compounds have not yet been proven to be
clinically useful for the treatment of neurodegenerative diseases.
Preclinical studies have beenperformed in various neurodegenera-
tive diseasemodels, however. The information obtained from such
studies could prove to be valuable for designing SIRT1-activating
molecules that may be more likely to be useful clinically. The
discovery of such molecules is becoming increasingly important,
considering the limitations of genetic manipulations and the lack
of unequivocal evidence of speciﬁc SIRT1 activation by prototype
molecules like resveratrol (Sauve, 2009).
Several rational strategies based on the available protein struc-
ture and the catalytic pathways have been designed to develop
small molecules that selectively activate sirtuins (Sauve, 2009).
One strategy involves designing resveratrol-like molecules, which
has not yielded successful results as the in vivo mechanism of
SIRT1 activation is not fully understood. Another approach aims
to increase the cellular levels of NAD+ in order to activate SIRT1
function. This approach has the advantage of harnessing a nat-
ural metabolic pathway to enhance SIRT1 functions. Moreover,
naturally occurring metabolites present the least risk of toxicity.
The efﬁcacies of agents that have been used to enhance NAD+
are still questionable, however, and NAD+ enhancement affects
a host of other physiological pathways, so that the approach is
not speciﬁc to SIRT1. A third strategy currently in the proof-
of-principle stage designated nicotinamide derepression is based
on countering the inhibitory effect of nicotinamide on sirtuins
by designing molecules that are antagonistic to nicotinamide.
This approach is still in its infancy and has not provided com-
pounds with desired potency, but is an attractive strategy to
develop further. Details of efforts to discover SIRT1-activating
molecules have recently been comprehensively reviewed by
Blum et al. (2011).
FUTURE PERSPECTIVES ON SIRT1
Over the last decade, our understanding of the biology of sirtuins
has vastly increased from its original description as an NAD+-
dependent class III histone deacetylase that can control the lifespan
of yeast. Of particular interest is the discovery that SIRT1 not only
deacetylates histones, but also some well-known transcriptional
regulators, thereby modulating a wide array of biological pro-
cesses. An exciting aspect is that SIRT1 mediates neuroprotection
against both acute and chronic neurological diseases. Importantly,
SIRT1 activity is enhanced by small-molecule compounds; there-
fore, development of small-molecule activators could lead to novel
therapies against neurological diseases. One of the broad pro-
tective mechanisms of SIRT1 is to suppress genome-wide gene
transcription via histone deacetylation. Furthermore, SIRT1 selec-
tively suppresses genes involved in fat storage, apoptosis, and
inﬂammation. Adding to the complexity of SIRT1-mediated cell
survival, SIRT1 speciﬁcally promotes the transcription of a set of
genes related to cell survival, energy metabolism, and mitochon-
drial biogenesis. SIRT1 thus has multifaceted mechanisms with
the end goal to increase cell viability.
Although extensively studied, the biological functions of SIRT1
remain only partially characterized. With respect to mechanism
of action, there are several substantial unknowns. For example,
it is not known how SIRT1 speciﬁcally increases transcription of
beneﬁcial genes while it simultaneously suppresses universal tran-
scription. It would be of interest to determine whether similar
mechanisms exist for genes upregulated by SIRT1-mediated acti-
vation of transcription. Another issue is the paradoxical effect of
SIRT1. For example, whereas SIRT1 directly suppresses PPARγ
transcriptional activity directly (Picard et al., 2004), it also acti-
vates PGC-1α (Nemoto et al., 2005; Rodgers et al., 2005), which
could increase the transcriptional activities of PPARγ (Puigserver
et al., 1998).
Although SIRT1 has been found to be neuroprotective in
numerous studies, it is clear from the diverse pathological mech-
anisms manifested in neurodegenerative disorders that the role
of SIRT1 requires more detailed study. The availability of crystal
structures and detailed mechanistic analysis are helpful in discov-
ering SIRT1 modulators, but would be of limited value if they
failed to reach clinical trials, thus emphasizing the importance
of developing robust animal models for investigating molecular
mechanisms involved in SIRT1 activation. Moreover, the poten-
tial negative effects of SIRT1 activation and energy depletion
need further investigation in animal models. The clinical success
of sirtuin activating compounds (STACs) in neurodegenerative
diseases relies overwhelmingly on developing new strategies and
designingmolecules based on the sirtuin chemistry andmolecular
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pathways activated by SIRT1. A very recent study performed by
Hubbard et al. (2013) demonstrated that the speciﬁc hydrophobic
motifs in SIRT1 substrates such as PGC-1α and FOXO3a facilitate
SIRT1 activation by STACs, implying that SIRT1 can be directly
activated through an allosteric mechanism common to chemi-
cally diverse STACs. In summary, there is no doubt that SIRT1
holds promising therapeutic potential for neurodegenerative
disorders.
SIRT3, ENERGY METABOLISM AND AGING
This section summarizes the studies on the role of mitochon-
drial SIRT3 in energymetabolism and protection against oxidative
stress and age-associated dysfunction (Figure 2).
SIRT3 AND MITOCHONDRIA
Mitochondria are not only the powerhouse for ATP production
but also the main sites where reactive oxygen species (ROS) are
generated and the intrinsic apoptotic signaling pathway is initiated
(Salminen et al., 2008b). The functions of mitochondrial proteins
are altered when they are deacetylated by NAD+-dependent mito-
chondrial deacetylases, including SIRT3, SIRT4, and SIRT5. All
mitochondrial sirtuins are present in the mitochondrial matrix
(Howitz et al., 2003; Rogina and Helfand, 2004). Since mitochon-
dria contain their own DNA, transcription factors, histone-like
proteins, and protein synthesis systems, mitochondrial sirtuins
deacetylate a set of targetswithin themitochondria that are distinct
from those of nuclear proteins (Tissenbaum and Guarente, 2001;
Wood et al., 2004). Although precise mechanistic information is
still lacking, evidence is emerging to suggest that mitochondrial
sirtuins protect against oxidative stress (Braunstein et al., 1993;
Baur et al., 2006).
Among the mitochondrial sirtuins, SIRT3 functions have been
characterized in the greatest detail. Initial studies of SIRT3-
deﬁcient mice indicated that loss of SIRT3, but not SIRT4 or
SIRT5, led to dramatic protein hyperacetylation withinmitochon-
dria, suggesting that SIRT3 is themajor mitochondrial deacetylase
activity (Dali-Youcef et al., 2007). In humans, full-length SIRT3
is a 44-kD protein with an N-terminal mitochondrial targeting
sequence that is an enzymatically inactive in vitro. It is proteolyt-
ically processed in mitochondria to a mature 28 kD catalytically
active deacetylase (Onyango et al., 2002; Schwer et al., 2002). The
ﬁrst mouse SIRT3 cDNA sequence identiﬁed encoded a 28-kD
protein lacking the N-terminal mitochondrial targeting sequence
(Yang et al., 2000). Several recent studies have identiﬁed a longer
isoform of murine SIRT3 encoding a 37 kD protein, however, that
can be imported intomitochondria and processed into themature
28 kD protein (Cooper et al., 2009; Jin et al., 2009; Bao et al., 2010;
Yang et al., 2010).Whether or not an active fraction of SIRT3 exists
FIGURE 2 | Schematic overview of molecular targets of SIRT3 and the role in regulating metabolism in mitochondria.
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outside mitochondria and modiﬁes extra-mitochondrial proteins
remains controversial.
SIRT3 AND METABOLIC HOMEOSTASIS
Emerging data have shown that one major function of SIRT3
is regulation of mitochondrial electron transport chain activ-
ity to maintain energy homeostasis. The main energy source in
mitochondria is pyruvate, a product of glycolysis. Alternatively,
mitochondria also burn fatty acids, amino acids, and acetates
when pyruvate is deﬁcient. For fatty acid catabolism, long-chain
acyl coenzyme A dehydrogenase (LCAD) is a key enzyme that
breaks down fatty acids and generates acetyl-CoA, stimulating
β-oxidation. In SIRT3 knockout mice, LCAD is hyperacetylated
at Lys42, leading to decreases in enzymatic activity, β-oxidation,
and ATP level (Hirschey et al., 2010). Interestingly, these mice do
not tolerate cold exposure during fasting (Hirschey et al., 2010).
SIRT3 directly deacetylates LACD at Lys42 and increases LACD
activity (Hirschey et al., 2010). In addition, SIRT3may promote β-
oxidation via multiple mechanisms, such as by deacetylating other
β-oxidation enzymes, including the short-chain L-3-hydroxyacyl-
CoA dehydrogenase and the very-long-chain acyl coenzyme A
dehydrogenase (Hallows et al., 2011), facilitating mitochondrial
adaptation to fuel changes.
Glucose is the major energy source for cells. When its avail-
ability is limited, however, alternative fuels become increasingly
important for cell survival. The ﬁrst step of glycolysis is the con-
version of glucose to glucose-6-phosphate, a reaction catalyzed by
hexokinases. It is reported that SIRT3 deacetylates cyclophilin D
(Hafner et al., 2010; Shulga et al., 2010), which leads to the dis-
sociation of hexokinase II and mitochondria, decreases glucose
metabolism, and stimulates oxidative phosphorylation (Shulga
et al., 2010).
Acetate derived from acetic acid and alcohol is also used as a
mitochondrial fuel, although this only occurs in extreme circum-
stances of nutrient depletion. In the initial step acetate is converted
to acetyl-CoA catalyzed by acetyl-CoA synthetases. Acetyl-CoA
synthetase 2 is the mitochondrial form of the enzyme. SIRT3
deacetylates acetyl-CoA synthetase 2 and enhances its activity,
leading to increased production of acetyl-CoA (Hallows et al.,
2006; Schwer et al., 2006). The acetyl-CoA from fatty acids and
acetates as well as α-ketoglutarate from amino acids can enter the
Krebs cycle. These two reactions are enhanced by SIRT3 (Hallows
et al., 2006; Schwer et al., 2006; Lombard et al., 2007; Schlicker
et al., 2008). Additionally, SIRT3 directly stimulates the Krebs
cycle. The third step of the cycle is the conversion of 6-carbon isoc-
itrate to 5-carbon α-ketoglutarate, a process catalyzed by isocitrate
dehydrogenase 2 (IDH2). A recent study shows that SIRT3 directly
deacetylates this dehydrogenase to increase its activity (Someya
et al., 2010).
NADH dehydrogenase 1 alpha subcomplex subunit 9
(NDUFA9) is an enzyme of mitochondrial complex I that is acety-
lated at Lys370 (Kim et al., 2006). SIRT3 physically interacts with
NDUFA9 and deacetylates it. SIRT3 knockout enhances its acety-
lation and reduces the activity of complex I (Ahn et al., 2008),
indicating that SIRT3 is a positive regulator of complex I. Com-
plex II, also known as succinate dehydrogenase, is composed of
four subunits, including the ﬂavoprotein succinate dehydrogenase
subunit A (SdhA). In SIRT3 knockout mice, SdhA is hyperacety-
lated at several lysine residues, and shows decreased activity of
complex II (Cimen et al., 2010). SIRT3 overexpression reverses the
acetylation of SdhA and increases complex II activity (Cimen et al.,
2010), indicating that SdhA is a SIRT3 substrate, and that SIRT3
is also a positive regulator of complex II.
SIRT3 is also reported to bind the alpha subunit 1 of the F1 par-
ticle of ATP synthase (Law et al., 2009), but the function is unclear.
Taken together, these results suggest that SIRT3promotesATPgen-
eration through enhancing action of several enzymes involved in
energymetabolism. Further supporting this role, SIRT3-knockout
mice show substantial acetylation of mitochondrial proteins, and
have reducedATP levels at baseline and during cellular stress (Ahn
et al., 2008).
Mitochondria are also the major sites for the generation of
the ROS, superoxide, and also where the superoxide is dis-
muted bymitochondrialMnSOD. Recent reports show that SIRT3
deacetylates MnSOD at Lys122 and increases its activity, reducing
oxidative and radiation stress in mice (Qiu et al., 2010; Tao et al.,
2010). Overexpression of SIRT3 protects HEK293 from oxidative
stress and prevents age-related cochlear cell death inmice (Someya
et al., 2010). Overall, this suggests anti-oxidative and neuroprotec-
tive roles of SIRT3. New data suggest that the SIRT3 deacetylase
plays a key role in bolstering mitochondrial anti-oxidant defenses
during CR (Qiu et al., 2010; Someya et al., 2010).
In future studies, it will be of interest to deﬁne the mechanism
whereby acetylation of electron transport chain subunits affects
generation of ATP. It is also important to elucidate why it might be
desirable under somephysiologic conditions to downregulate elec-
tron transport chain activity by increased acetylation. As an added
wrinkle, SIRT3 negatively regulates translation within mitochon-
dria by deacetylating the ribosomal protein MRPL10, a function
proposed to reduce respiration (Yang et al., 2010).
SIRT3 levels are increased in adipose tissue, skeletal mus-
cle, and liver during CR (Shi et al., 2005; Palacios et al., 2009;
Schwer et al., 2009; Hirschey et al., 2010), and conversely decline
in response to high-fat feeding (Palacios et al., 2009; Bao et al.,
2010; Kendrick et al., 2011). These expression data suggest that
SIRT3 might play a role in the response to metabolic homeostasis.
In mammals, two independent studies showed that SIRT3 inter-
acts with and deacetylates acetyl-CoA synthetase 2 (AceCS2) at
the active site lysine to promote AceCS2 activity (Hallows et al.,
2006; Schwer et al., 2006). Under fed conditions, the majority
of acetyl-CoA is generated through metabolism of pyruvate by
Pyruvate dehydrogenase complex (PDC) and by fatty acid β-
oxidation, largely bypassing the need for AceCS2. In this regard,
studies of AceCS2-deﬁcient mice revealed that AceCS2 is speciﬁ-
cally required for metabolic homeostasis when the mice are fed a
low carbohydrate/high fat diet (LC/HFD); AceCS2-deﬁcient ani-
mals are essentially normal on a chow diet but show poor weight
gain, hypothermia, hypoglycemia, and impaired survival on an
LC/HFD (Sakakibara et al., 2009). Presumably the role of SIRT3
in regulating AceCS2 could also be important during fasting,
when acetate can be used as a source of energy in extrahepatic
tissues (Hirschey et al., 2010). Indeed, SIRT3 has recently been
shown to deacetylate and activate 3-hydroxy-3-methylglutaryl-
CoA synthase 2 (HMGCS2), amitochondrial enzyme that converts
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acetyl-CoA into ketone bodies (acetoacetate, β-hydroxybutyrate,
and acetone) in the liver under fasting conditions, which can in
turn be used as a source of energy in certain tissues including the
brain (Shimazu et al., 2010). SIRT3-deﬁcient mice are unable to
produce normal levels of ketone bodies upon fasting.
SIRT, LIFESPAN AND AGE-ASSOCIATED PHENOTYPES
The role of SIRT3 in aging is of considerable interest because it
appears to suppress ROS, one of the causes contributing to the
process of aging. In addition to elucidating its roles in regulat-
ing speciﬁc biochemical pathways in mitochondria, there is great
interest in testing whether SIRT3 might modulate age-associated
phenotypes, or indeed lifespan itself. In this regard, some studies
have linked polymorphisms in the SIRT3 genomic locus to human
longevity, although others have failed to demonstrate this associa-
tion (Rose et al., 2003; Bellizzi et al., 2005, 2007; Lescai et al., 2009).
A polymorphism associated with decreased SIRT3 mRNA expres-
sion was present in cohorts of young but not old men, suggesting
that reduced SIRT3 expression may be detrimental to survival in
old age (Bellizzi et al., 2005, 2009). In sedentary individuals, SIRT3
protein expression declined with age in skeletal muscle mito-
chondria, concomitant with a reduction in respiratory function
(Lanza et al., 2008).
Age-related hearing loss (ARHL) is a common problem in the
elderly, occurring secondary to cell loss and other degenerative
changes in the cochlea. An elegant study has ﬁrmly established
a role for SIRT3 in preventing ARHL (Someya et al., 2010). One
mechanism by which SIRT3 mediates this effect is by deacetyla-
tion of IDH2 (Schlicker et al., 2008; Someya et al., 2010), which
converts isocitrate to α-ketoglutarate concomitant with reduction
of NADP+. NADPH in turn allows regeneration of reduced glu-
tathione to promote mitochondrial oxidative defense. In response
to CR, wild-type mice, but not SIRT3-deﬁcient animals, show
increased NADPH levels, increased reduced glutathione in mito-
chondria, and decreased DNA damage in the cochlea and in other
tissues. In tissue culture cells, overexpression of SIRT3 or IDH2
protects against oxidative stress-induced cell death, and the two
proteins together have a synergistic pro-survival effect. These
results do not rule out the possibility that SIRT3 might modify
other substrates in addition to IDH2 to prevent AHRL during CR.
Similarly, Qiu et al. (2010) reported that SIRT3-deﬁcient mice fail
to suppress ROS levels and macromolecular damage during CR.
They ﬁnd that SIRT3 directly deacetylates SOD2 to increase its
activity during CR, whereas SIRT3-deﬁcient mice do not show
SOD2 deacetylation in response to this diet (Qiu et al., 2010).
Overall, these papers point to crucial role for SIRT3 in suppressing
oxidative damage and its negative sequel during CR. It remains
to be seen how SIRT3, or the other mitochondrial sirtuins, might
affect other phenotypes of aging and/or effects of CR. The reduc-
tion of serum insulin and triglycerides that normally occurs during
CR is not observed in SIRT3-deﬁcient mice (Someya et al., 2010),
implying that SIRT3 plays additional, uncharacterized roles in the
adaptation to this dietary regimen. A recent study indicates that
upregulation of SIRT3 indeed reverses aging-associated degener-
ation in hematopoietic stem cells (Brown et al., 2013), and SIRT3
may promote organismal longevity by maintaining the integrity
of tissue-speciﬁc stem cells.
SIRT3 AND MITOCHONDRIAL PROTEIN ACETYLATION: UNRESOLVED
QUESTIONS
Acetylation of mitochondrial proteins plays a major role in reg-
ulating functions of this organelle. Despite the rapid progress
in this area, there are still many outstanding questions remain
that will no doubt provide fruitful avenues for research for years
to come. In particular, how mitochondrial proteins are acety-
lated in the ﬁrst place is currently unknown. The identity of
putative mitochondrial acetyltransferases remains elusive; iden-
tiﬁcation of such proteins would represent a major step forward
in this ﬁeld. Alternatively, or in addition to enzymatic acetylation
within mitochondria, mitochondrial proteins could in principle
be acetylated outside this organelle, before or concomitant with
mitochondrial import or even be acetylated non-enzymatically.
These latter models would not permit rapid cycles of acetyla-
tion/deacetylation of mitochondrial proteins to regulate target
protein function in response to varied environmental challenges.
Instead, after deacetylation, restoration of acetylation status would
require new protein synthesis. Such models could be distin-
guished through pulse-chase experiments assessing acetylation
of newly synthesized mitochondrial proteins before and after
mitochondrial import.
Similarly, how SIRT3 activity is regulated in the mitochondria
is incompletely understood. SIRT3 requires NAD+, and there-
fore mitochondrial NAD+ levels play a critically important role in
governing mitochondrial SIRT3 function. Increased NADH gen-
eration from NAD+ that occurs with HFD and leads to reduced
SIRT3 function may explain the increased global mitochondrial
protein acetylation observed during this diet, as could increase
levels of acetyl-CoA, the substrate for acetyltransferases (Kendrick
et al., 2011). This overall increased acetylation may represent the
net effect of increased acetyltransferase activity superimposed
upon elevated SIRT3 function; alternatively, some protein species
hyperacetylated during CR or other conditions may not be sub-
strates for mitochondrial SIRT3. The activity of SIRT3 and other
mitochondrial sirtuins might be inﬂuenced by other conditions in
addition to NAD+ levels, such as post-translational modiﬁcation
or interactions with regulatory proteins.
It is currently unclear whether interventions that have an
impact on acetylation of many mitochondrial proteins – SIRT3
deﬁciency, such as CR, HFD – lead to modiﬁcation of common
sets of proteins on the same lysine sites, or whether this response
is tailored to different environmental perturbations. Similarly, it
remains unclear whether the mitochondrial sirtuins share com-
mon targets and/or functions in common. This question could
be addressed in mice or cells with mitochondrial sirtuin deﬁ-
ciencies or knockdowns. Given that SIRT3 deacetylates many
proteins inmitochondria aswell as suppresses some age-associated
phenotypes, it will be of interest to test whether acetylation of
mitochondrial proteins changes with age, either individually or
globally, and whether prevention of this effect might have a
beneﬁcial effect on health span or even lifespan.
In addition, whereas the functional impact of acetylation on
a few individual protein targets is clear, a global understand-
ing of how SIRT3 affects the activity of metabolic pathways in
mitochondria, cells, tissues, and the organism overall is still
lacking. Answers to these and related questions involving SIRT3
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and mitochondrial protein acetylation will no doubt reveal novel
aspects of mitochondrial biology, and perhaps ultimately pro-
vide the basis for novel therapeutic strategies for a variety of
disorders.
FURTHER PERSPECTIVES
In the past decade, the function of mammalian sirtuins has been
investigated in greater detail than ever before, and we now have
a much better molecular understanding of the multiple roles
this unique family of enzymes plays in seemingly every biolog-
ical process. There is little doubt that sirtuins have emerged as
critical modulators of metabolic adaptive responses, and their
activities have been linked to metabolic abnormalities as well as
age-associated neurodegeneration. Yet, key questions will keep
investigators busy in the coming years. We still have poor under-
standing of the molecular mechanisms regulating expression and
activity of the sirtuins, and of the precise stimuli that regulate these
proteins, and whether the activities of different sirtuins are regu-
lated in a coordinated fashion. In other words, is there cross-talk
between sirtuins? Will future studies cement the argument that
sirtuins are, indeed, critical modulators of lifespan? This review
has focused on SIRT1 and SIRT3. Even less is known about other
sirtuins. Further investigation into the targets and functions of
this unique family of sirtuins will help develop new strategies
for protection against and recovery from common aging-related
neurological diseases and promote successful aging.
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